scholarly journals Treatment of hairy cell leukemia with recombinant alpha-interferon

Blood ◽  
1986 ◽  
Vol 68 (2) ◽  
pp. 493-497 ◽  
Author(s):  
JR Quesada ◽  
EM Hersh ◽  
J Manning ◽  
J Reuben ◽  
M Keating ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Tumor Burden ◽  
Newly Diagnosed ◽  
Hairy Cell ◽  
Blood Products ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Mediastinal Adenopathy ◽  
Recombinant Interferon Alpha

Abstract Thirty patients with hairy cell leukemia were treated with recombinant interferon alpha-A (rIFN alpha A; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFN alpha A was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN alpha A is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.

scholarly journals Treatment of hairy cell leukemia with recombinant alpha-interferon

Blood ◽  
1986 ◽  
Vol 68 (2) ◽  
pp. 493-497 ◽  
Author(s):  
JR Quesada ◽  
EM Hersh ◽  
J Manning ◽  
J Reuben ◽  
M Keating ◽  
...  
Keyword(s):  
Hairy Cell Leukemia ◽  
Tumor Burden ◽  
Newly Diagnosed ◽  
Hairy Cell ◽  
Blood Products ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Mediastinal Adenopathy ◽  
Recombinant Interferon Alpha

Thirty patients with hairy cell leukemia were treated with recombinant interferon alpha-A (rIFN alpha A; Roferon-A); seven were previously untreated. Nine complete and 17 partial remissions were documented by bone marrow core biopsies. All patients' peripheral blood hematologic indexes either improved or normalized. Twelve of 13 patients with retroperitoneal or mediastinal adenopathy obtained remissions of tumor masses. All seven patients with splenomegaly showed prompt reduction in the size of the spleen to normal size. The incidence of complete remissions was significantly higher (P = .02) in previously untreated patients (5 of 7) than in those in whom splenectomy had been performed (4 of 23), a result presumed to be related to the pretreatment tumor burden. rIFN alpha A was well tolerated; mild fatigue was the most frequent complaint. In most patients, tumor remissions resulted in an improved quality of life: they eliminated the need for transfusing blood products and reduced the incidence of infections, and immune deficits were apparently restored in some of the patients. We conclude that rIFN alpha A is an effective therapy for all stages of hairy cell leukemia including previously untreated or newly diagnosed patients.

Recombinant interferon alpha-C for advanced hairy cell leukemia. An Israeli multicenter study

Cancer ◽  
1988 ◽  
Vol 61 (11) ◽  
pp. 2207-2213 ◽  
Author(s):  
Dan Aderka ◽  
Rita Michalevicz ◽  
Yair Daniel ◽  
Yoram Levo ◽  
Dan Douer ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Multicenter Study ◽  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

Pleural Involvement in Hairy Cell Leukemia Response to Recombinant Interferon-Alpha

CHEST Journal ◽  
1990 ◽  
Vol 98 (6) ◽  
pp. 1544 ◽  
Author(s):  
François Raffi ◽  
Geneviève Magadur ◽  
Maryse Fiche ◽  
Dominique Merrien ◽  
Jacques H. Barrier ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Pleural Involvement ◽  
Recombinant Interferon Alpha

Human recombinant interferon-alpha in the treatment of patients with hairy cell leukemia

1988 ◽  
Vol 10 ◽  
pp. 102
Author(s):  
A.B. Skotnicki ◽  
T. Wolska-Smolen ◽  
J. Blicharski ◽  
A. Zdunczyk ◽  
U. Sasiadek ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Recombinant Interferon Alpha

scholarly journals Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a [see comments]

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 839-845 ◽  
Author(s):  
E Berman ◽  
G Heller ◽  
S Kempin ◽  
T Gee ◽  
LL Tran ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hairy Cell Leukemia ◽  
Interferon Alfa ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Minor Response ◽  
Recombinant Interferon ◽  
Long Term Follow Up

Abstract Thirty-five evaluable patients with hairy cell leukemia (HCL) were treated with recombinant interferon alfa-2a (rIFN-alpha 2a), given at a dose of 3 X 10(6) units (U) intramuscularly (IM) daily for 6 months followed by 3 X 10(6) U IM three times a week for an additional 18 months in a single institution study. All treatment was stopped after 24 months. Sixty-nine percent of patients achieved a partial response, 11% a minor response, and 3% (one patient) had stable disease. Six patients (17%) did not respond to rIFN-alpha 2a. Two patients (6%) achieved a response but later progressed on treatment. A total of 23 patients completed 2 years of treatment and are evaluable for long-term follow-up at a median of 20 months postcompletion of therapy (range 9 to 32 months). Eleven patients (48%) have had progression of their disease at a median of 10 months (range .5 to 25 months) after treatment was discontinued. Statistical analysis of pretreatment patient characteristics did not reveal any factor(s) associated with a high probability of responding to rIFN-alpha 2a; however, analysis of post-treatment variables measured after 2 years of treatment suggested that a low platelet count was associated with a high rate of disease progression. These findings are compared with other published trials using rIFN-alpha 2b, a similar but not identical rIFN preparation. We conclude that while rIFN-alpha 2a has a high overall response incidence, the rate of disease progression after therapy is discontinued approaches 50%, and that a subset of patients can be identified who are at high risk for recurrence after completing 2 years of treatment.

scholarly journals Effective natural interferon-alpha therapy in recombinant interferon- alpha-resistant patients with hairy cell leukemia

Blood ◽  
1991 ◽  
Vol 78 (1) ◽  
pp. 38-43 ◽  
Author(s):  
P von Wussow ◽  
H Pralle ◽  
HK Hochkeppel ◽  
D Jakschies ◽  
S Sonnen ◽  
...  
Keyword(s):  
Interferon Alpha ◽  
Hairy Cell Leukemia ◽  
Mononuclear Cells ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Recombinant Interferon ◽  
Homologous Protein ◽  
Ifn Alpha ◽  
Interferon Alpha Therapy ◽  
Alpha Therapy

Abstract To explore the relationship between anti-interferon-alpha (anti-IFN- alpha) antibodies and loss of clinical responsiveness to IFN-alpha treatment, we examined sera from 59 patients with hairy cell leukemia who responded to therapy with recombinant IFN-alpha-2a (rIFN-alpha-2a). During the first 2 years of therapy, 10 patients developed rIFN-alpha- 2a-neutralizing and 15 rIFN-alpha-2a-binding antibodies. Nine of the 59 initially responding patients became resistant to rIFN-alpha-2a and suffered a relapse of the disease at 7 to 24 months of treatment. All nine relapsing patients tested positive for both neutralizing and binding antibodies with titers above 400 INU/mL, while none of the antibody-negative patients relapsed. Six patients with detectable binding antibody titers below 400 INU/mL continued to respond to treatment. By measuring the IFN kinetics and the levels of the IFN- induced Mx-homologous protein in mononuclear cells after a single injection each of rIFN-alpha-2a and nIFN-alpha the IFN antibodies of eight of the nine resistant rIFN-alpha patients were found to be highly specific for rIFN-alpha-2a. Therefore, these eight patients were switched to natural IFN-alpha (nIFN-alpha) therapy at doses of 3 million IU, three times a week. All eight patients responded to treatment with nIFN-alpha, achieving durable objective responses similar to those obtained previously with rIFN-alpha-2a. These data clearly demonstrate that rIFN-alpha antibody-positive patients can effectively be treated with nIFN-alpha.

Sign in / Sign up

Export Citation Format

Share Document